CME Symposium
In Association with the 21st WCIRDC

Winning the Trifecta of Diabetes, Heart Disease, and Kidney Disease

Thursday December 7, 2023
7:30pm – 9:15pm PST
Hilton Universal City Hotel
Los Angeles, California

DINNER WILL BE SERVED

This is a CME Symposium Supported by an Educational Grant from AstraZeneca

Free for all 21st WCIRDC Attendees | Register Online: wcir.org/registration

This CME Symposium will be available and FREE for ONE year following the meeting.

Provided By: MEEF Foundation, PESI, CME ABIM-MOC Accredited

Administered By: TMIOA
WINNING THE TRIFECTA OF DIABETES, HEART DISEASE, AND KIDNEY DISEASE

CHAIRS: Muthiah Vaduganathan, MD, MPH • Yehuda Handelsman, MD

Program Description
This satellite symposium will explore the changing landscape of therapies for the trifecta of diabetes, HF, and CKD. The program will address gaps in physicians’ knowledge of the interconnections between diabetes, CKD, and heart failure and how to comprehensively manage these conditions when anyone, two, or all three are present in the same patient. The program will also address the management of patients with heart failure and CKD with no diabetes.

Learning Objectives
Upon completion of this CME symposium, participants should be able to:
• Understand the impact of early therapeutic interventions on the pathophysiologic pathways underlying the development of CKD and HF in patients with diabetes.
• Review evidence supporting the use of SGLT2 inhibitors across a wide range of patient populations with CKD.
• Describe Guidelines directed to medical therapy for patients with heart failure.
• Implement medical therapy regimens for patients with comorbid diseases, including those with HF and CKD, with and without diabetes.

Target Audience
This educational initiative is designed for cardiologists, endocrinologists, nephrologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of people with Heart failure or Type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.

7:30 pm – 9:15 pm        Dinner CME Symposium        Supported by AstraZeneca

7:30 pm        Introduction & Pre-CME Questions
Muthiah Vaduganathan, MD, MPH

7:50 pm        Early intervention in Diabetes addressing pathophysiology in preventing comorbidities
Vivian A. Fonseca, MD

8:10 pm        SGLT2i effects across the spectrum of CKD and multiple Populations
Peter Rossing, MD

8:30 pm        Impact of SGLT2i on HF Outcomes in Various Populations & the range of LVEF
Muthiah Vaduganathan, MD, MPH

8:50 pm        Panel Discussion and Q&A: Changing the Trajectory of Heart Failure and CKD, Implementing Guidelines Directed Medical Therapy
Panel: Vivian A. Fonseca, MD · Christian W. Mende, MD
Erin D. Michos, MD · Peter Rossing, MD · Muthiah Vaduganathan, MD
Moderator: Yehuda Handelsman, MD

9:10 pm        Concluding Remarks & Post-CME Questions

9:15 pm        Adjourn

CME DINNER SYMPOSIUM
This CME symposium is FREE for 21st WCIRDC attendees and will stay on-demand for ONE year following the meeting.
Learn more: WCIR.ORG/CMEsymposium
To register for the entire 21st WCIRDC meeting
Please visit: wcir.org/registration

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

PESI, Inc., designated this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s).
Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information please contact:
info@tmioa.com or 818 342 1889
This is a CME Program Supported by an Educational Grant from AstraZeneca